Article Sidebar
Views pdf: 25
EFFICACY OF FIRST-LINE VINORELBINE PLUS TRASTUZUMAB IN BREAST CANCER HER2 POSITIVE RECURRENT
Main Article Content
Abstract
Objective: To evaluate the effectiveness of vinorelbine plus trastuzumab in first-line of breast cancer HER2 positive recurrent at Institute of Oncology and Nuclear Medicine, Military Hospital 175. Subject and methods: A retrospective descriptive study of 35 patients diagnosed of breast cancer HER2 positive recurrent from 1/2019 to 10/2022 at Institute of Oncology and Nuclear Medicine, Military Hospital 175. Result: The overall response rate was 60,0%, in which there were 37,8% complete response, clinical benefit rate was 82,9%. The overall response rate for patients with nonvisceral metastases was significantly higher in patients with visceral metastases (86,7% versus 40,0%, p = 0,005). Common toxicities were leukopenia 40,0%, neutropenia 65,7%, anemia 60,0%, increased AST/ ALT 68,6%, nausea/ vomiting 22,9%, grade 1 – 2 toxicities were common, grade 3 – 4 toxicities were rare. Conclusion: Regimen of vinorelbine plus trastuzumab in breast cancer HER2 positive recurrent is an effective and safe regimen, patients are well tolerated.
Article Details
Keywords
breast cancer recurrent, HER2 positive, vinorelbine, trastuzumab
References
2. National Cancer Institute. Cancer stat facts: female breast cancer. Surveillance, Epidemiology, and End Results Program. Accessed May 15, 2024. https://seer.cancer.gov/statfacts/html/ breast.html
3. Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2 overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007; 110(5):965-72.
4. Ibragimova KIE, Geurts SME, Meegdes M, et al. Outcomes for the first four lines of therapy in patients with HER2 positive advanced breast cancer: results from the SONABRE registry. Breast Cancer Res Treat. 2023;198(2):239-251.
5. Vũ Thị Trang, Lê Thanh Đức, Nghiêm Thị Minh Châu và cộng sự. Đánh giá kết quả bước đầu hóa trị vinorelbine kết hợp trastuzumab trên bệnh nhân ung thư vú di căn có HER2 dương tính tại bệnh viện K. Tạp chí Y học Việt Nam. 2019;481(2):79-83.
6. Đinh Thị Lan Anh. Đánh giá kết quả đơn trị liệu vinorelbine trong ung thư vú tái phát di căn. Luận văn thạc sĩ Y học. Trường Đại học Y Hà Nội; 2016.
7. Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol. 2011;29(3):264-71.
8. Lê Thanh Đức, Bùi Thành Lập. Hiệu quả điều trị bước 1 phác đồ docetaxel kết hợp trastuzumab trên ung thư vú HER2 dương tính tái phát, di căn tại bệnh viện K. Tạp chí Y học lâm sàng bệnh viện Trung ương Huế. 2023;85:132-138.
9. Perez EA, López-Vega JM, Petit T, et al. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2 positive locally advanced or metastatic breast cancer: VELVET cohort 1 final results. Breast Cancer Res. 2016;18(1):126.